靶向突触 NMDA 受体共激动剂作为阿尔茨海默病的治疗方法？

Targeting Synaptic NMDA Receptor Co-agonism as a Therapy for Alzheimer's Disease?

机构信息

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh EH16 4SB, UK; Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK.

出版信息

Cell Metab. 2020 Mar 3;31(3):439-440. doi: 10.1016/j.cmet.2020.02.009.

DOI:10.1016/j.cmet.2020.02.009

PMID:32130875

Abstract

Alzheimer's disease (AD) is associated with lower brain glucose metabolism. In this issue, Le Douce et al. (2020) show that this leads to insufficient astrocyte-dependent production of D-serine, co-agonist of synaptic NMDA receptors. Oral L-serine therapy rescues NMDA receptor hypofunction, plasticity, and cognition in an AD model, suggesting a new therapeutic strategy.

摘要

阿尔茨海默病（AD）与大脑葡萄糖代谢降低有关。在本期中，Le Douce 等人（2020 年）表明，这导致星形胶质细胞依赖性 D-丝氨酸产生不足，而 D-丝氨酸是突触 NMDA 受体的共激动剂。口服 L-丝氨酸治疗可挽救 AD 模型中的 NMDA 受体功能低下、可塑性和认知功能，提示了一种新的治疗策略。